Additionally, the 36-month beta value for FATE is 2.23. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 7 rating it as “hold,” and 0 rating it as “sell.”
The public float for FATE is 107.09M and currently, short sellers hold a 12.02% ratio of that float. The average trading volume of FATE on June 04, 2025 was 2.00M shares.
FATE) stock’s latest price update
The stock price of Fate Therapeutics Inc (NASDAQ: FATE) has jumped by 4.04 compared to previous close of 1.36. Despite this, the company has seen a gain of 11.42% in its stock price over the last five trading days. globenewswire.com reported 2025-05-30 that SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years’ experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy’s appointment.
FATE’s Market Performance
FATE’s stock has risen by 11.42% in the past week, with a monthly rise of 20.94% and a quarterly rise of 56.34%. The volatility ratio for the week is 7.09% while the volatility levels for the last 30 days are 7.22% for Fate Therapeutics Inc The simple moving average for the past 20 days is 21.59% for FATE’s stock, with a -29.06% simple moving average for the past 200 days.
Analysts’ Opinion of FATE
Piper Sandler, on the other hand, stated in their research note that they expect to see FATE reach a price target of $6, previously predicting the price at $4. The rating they have provided for FATE stocks is “Overweight” according to the report published on June 17th, 2024.
Wells Fargo gave a rating of “Equal Weight” to FATE, setting the target price at $6 in the report published on March 27th of the previous year.
FATE Trading at 30.04% from the 50-Day Moving Average
After a stumble in the market that brought FATE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.10% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at FATE starting from Wolchko J Scott, who proposed sale 113,178 shares at the price of $0.93 back on Mar 06 ’25. After this action, Wolchko J Scott now owns shares of Fate Therapeutics Inc, valued at $104,881 using the latest closing price.
Bressi Jerome Charles, the insider of Fate Therapeutics Inc, sale 5,980 shares at $1.55 during a trade that took place back on Jan 10 ’25, which means that Bressi Jerome Charles is holding 270,203 shares at $9,269 based on the most recent closing price.
Stock Fundamentals for FATE
Current profitability levels for the company are sitting at:
- -15.03 for the present operating margin
- -1.59 for the gross margin
The net margin for Fate Therapeutics Inc stands at -13.19. The total capital return value is set at -0.54. Equity return is now at value -49.23, with -36.32 for asset returns.
Based on Fate Therapeutics Inc (FATE), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -1.48.
Currently, EBITDA for the company is -176.58 million with net debt to EBITDA at -0.23. When we switch over and look at the enterprise to sales, we see a ratio of 15.04. The receivables turnover for the company is 5.54for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.81.
Conclusion
In conclusion, Fate Therapeutics Inc (FATE) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high..
